Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss

Condition:   Carcinoma, Squamous Cell of Head and Neck
Interventions:   Drug: Copanlisib;   Drug: Cetuximab
Sponsor:   UNICANCER
Recruiting - verified June 2016

from #ORL via xlomafota13 on Inoreader http://ift.tt/29fNU37
via IFTTT